Share Price, page-7536

agree with Benny.

I think Neuren would only consider takeover offers as viable based on market data.

For e.g. I would think they are looking at the size of the population the drug might help, the likely price each drug would fetch, the number of indications NZ 2591 is effective in, the partners interested coming to the table - whether these are global or just regional??

shareprice has little influence over that final takeover offer value that Neuren will accept, I feel (all my opinion only). shareprice is such a volatile, arbitrary number, and basing the acceptance of a low takeover offer on **just** shareprice is a disservice to the decades of work, and the science...

I am hopeful that the leaders and decision makers at Neuren will see beyond Shareprice before closing any future deals.

excited for these results to be read out!